Exploration study on the effect of rhIL1Ra on endothelial function in patients with gout

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500097697

Enrollment

Unknown

Registered

2025-02-24

Start date

2025-03-01

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout

Interventions

Observation group:None

Eligibility

Sex/Gender

Male

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients who have completed the Phase I clinical trial evaluating the safety and pharmacokinetic characteristics of recombinant human interleukin-1 receptor antagonists for injection in patients with gouty arthritis in the intermittent phase or the multicenter Phase IIa clinical trial evaluating the safety and efficacy of UA007 in patients with acute attacks of gouty arthritis at our center; 2. During the participation in clinical trials, the informed consent form for biological samples and health-related information donors has been signed.

Exclusion criteria

Exclusion criteria: The sample is not suitable for testing, including sample contamination, sample hemolysis, insufficient sample size, etc.

Design outcomes

Primary

Measure	Time frame
asymmetric dimethylarginine;endothelin-1;malondialdehyde;protein carbonyls,PCO;nitro tyrosine;vascular cell adhesion molecule-1;intercellular cell adhesion molecule-1;E-Selectin;IL-1ß;IL-6;IL-8;IL-18;proteomic analysis;	—

Countries

China

Contacts

Public ContactJiang Lindi

Zhongshan Hospital,Fudan University

jiang.lindi@zs-hospital.sh.cn+86 186 1688 0752

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026